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In the Western world, the diagnosis and management of Plasmodium vivax malaria in pregnant women can be
challenging, and the pathogenesis of adverse outcomes for both the mother and the foetus is still poorly known.
The authors describe the case of a 29-year-old Pakistani woman at the 29th week of her second pregnancy, who
was admitted to the Hospital following the abrupt onset of fever. At the time of admission, she had been living in
Italy without travelling to any malaria-endemic areas for eight months. She was diagnosed with vivax malaria after a
thin blood smear revealed the presence of plasmodial trophozoites and gametocytes and treated accordingly. Due
to the onset of oligohydramnios, she underwent caesarian section at the 31st week of pregnancy with no further
complications. Histological examination of the placenta showed no evidence of plasmodial infection, but was
inconclusive. It is unclear whether oligohydramnios is a complication of pregnancy-related Plasmodium vivax
malaria. Given the long latency of hypnozoites, every febrile pregnant patient with a previous stay in an endemic
area should be screened for malaria with a thick and a thin blood smear.
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Every year approximately 50 million women living in
malaria-endemic areas become pregnant [1]: it is esti-
mated that 10,000 women and 200,000 infants die as a
result of malaria complications during pregnancy. Plasmo-
dium falciparum is the most frequent cause of severe
clinical manifestations, including maternal anaemia, pre-
maturity, and low birth weight. However, Plasmodium
vivax malaria can also cause some of the same complica-
tions as P. falciparum infection, although less commonly.
Most clinical manifestations are nonspecific and vari-
able. Fever is the main sign, usually accompanied by
chills and sweats. Other common symptoms include
headache, myalgias, fatigue, nausea and vomiting, ab-
dominal pain and diarrhoea. Pregnant women are more
susceptible than non-pregnant women to develop com-
plications, such as hypoglycaemia, pulmonary oedema
and acute respiratory distress syndrome [2]. Appro-
ximately 60 percent of pregnant women are anaemic
as a result of malarial infection [3,4], and anaemia may
be the only finding of the disease [5]. Malaria during* Correspondence: a.malfitano@smatteo.pv.it
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in the newborn, including miscarriage, foetal growth re-
striction/small for gestational age (SGA) infant, preterm
birth (<37 weeks of gestation), low birth weight (LBW)
(<2500 g at birth), congenital and post-partum infection,
and perinatal death [3,6-9].Case presentation
A 29-year-old Pakistani woman, gravida 2 para 1, at the
29th + 6 week of her second pregnancy, was admitted to
the Emergency Room (E.R.) of San Matteo Hospital Foun-
dation (Pavia, Italy) on the 30th of May 2012 following the
abrupt onset of fever and malaise and was then transferred
to the Obstetrics and Gynecology (OB/GYN) Department.
The woman was born and had always lived in Pakistan
until eight months before admission when she moved to
Italy and had been living there thenceforth. She reported
having been well until the day before admission. She de-
nied any history of previous disease. Her first pregnancy
was uncomplicated, and she delivered a healthy newborn
at the 40th week. On entrance, she was febrile (38°C).
Her physical examination was unremarkable. Blood
pressure was 120/70 mmHg and the remainder of her
vital signs were normal.Ltd. This is an Open Access article distributed under the terms of the Creative
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11.5 g/dl, 33.7% haematocrit (Hct) and a mild neutrophilic
leukocytosis (WBC 10.6 × 109/L: neutrophils 8.2 × 109/L).
She was started on ampicillin (1 g tid) and paracetamol.
Fever subsided, and cardiotocography (CTG) did not
reveal any signs of foetal distress. Three days after the be-
ginning of treatment, fever with shivers recurred in associ-
ation with lumbar and leg pain. Gentamicin (80 mg tid)
was added, and then, on the basis of the Infectous Disease
(I.D.) consult, antibiotic therapy was switched into pipera-
cillin/tazobactam (4.5 g tid) in order to cover a possible
urinary tract infection. The patient remained afebrile for
one day, when blood tests showed an increase of bilirubin
(total 2.80 mg/dl; direct 1.48 mg/dl) and a decrease of
haemoglobin (Hb 10.8 g/dl, Hct 32.7%). The next day the
temperature rose to 39.8°C, the haemoglobin value
dropped to 10.3 g/dl, and an abnormal foetal heart rate
variability was recorded on the CTG. In order to rule
out pneumonia, a chest X-ray was performed under a
protective abdominal shield and resulted negative. A
hematological consult was obtained, too, and a thin blood
smear was examined, detecting the presence of Plasmo-
dium spp. The I.D. specialist identified trophozoites and
gametocytes from Plasmodium vivax, thus enabling the
diagnosis of P. vivax pregnancy-associated malaria. Quin-
ine sulphate (500 mg tid) was immediately administered,
and therapy was continued for seven days.
During malaria treatment, the patient remained
afebrile and asymptomatic. One week after the initiation
of therapy, the haemoglobin level increased to 11.8 g/dl
and bilirubinaemia returned to normal values (total
0.95 mg/dl). At the same time (31st week), an ultrasound
exam showed the presence of oligohydramnios, and the
amniotic fluid index (AFI) was 16 mm. As a matter of
fact, four previous ultrasound exams, the first two pre-
ceding quinine administration, had shown a progressive
decrease of the amniotic fluid index. The patient under-
went a premature rupture of membranes (PROM) test,
which was negative, and a caesarean section followed,
with no further complications.
Thin blood smears were obtained from both umbilical
and peripheral blood of the newborn, tested for malaria
parasites, and resulted negative. Concurrently, the antigen
test (Alere BinaxNOW®, Milan, Italy) was performed on
the umbilical blood and turned out to be negative. Further-
more, the histological exam of the placenta was requested,
but no pathological evidence of infection was observed.
The patient was then discharged, and a follow-up appoint-
ment was scheduled to initiate the eradication therapy
through the long-term administration of primaquine.
Discussion
Infection from P. vivax in pregnancy has traditionally been
considered less severe as compared to P. falciparummalaria. This is believed to be related to the lack of pla-
cental sequestration in P. vivax infection and the parasite
tropism for reticulocytes accounting for a milder form of
anaemia [10,11]. The patient’s lowest haemoglobin level
was 10.3 g/dl. Nevertheless, especially in undiagnosed pa-
tients, pregnancy-related P. vivax infection correlates
with a significant risk of adverse maternal and foetal out-
comes, and a prompt diagnosis is of paramount import-
ance to assess the prognosis quoad vitam and quoad
valetudinem of both the foetus and the mother [12-14].
This case highlights the major issues of the diagnostic
process and the clinical management of P. vivax infection
in pregnant women.
The diagnosis of malaria was made only one week
after admission. The patient was born in Pakistan but
she had not travelled to any malaria endemic areas for
nearly one year. Hence, the correlation between the on-
set of fever and other nonspecific symptoms and malar-
ial infection was not promptly considered. Lumbar pain
and intermittent fever, despite the initiation of ampicillin
therapy, skewed the differential diagnosis toward a
urinary tract infection. Nonetheless, the diagnosis of
pregnancy-associated malaria could not be excluded. In-
deed, P. vivax and Plasmodium ovale infections may
result in a long period of clinical latency due to the pres-
ence of hepatic hypnozoites, which can re-activate weeks,
or even months, after the exposure to the parasite. In this
case, the onset of symptoms was eventually demonstrated
to be caused by P. vivax malaria nearly one year after the
last exposure. Thus, the suspicion of pregnancy-associated
malaria should be elicited in any febrile pregnant woman
with a previous stay in a malarious region and malaria
screening tests should be always performed.
A second major issue of pregnancy-related malaria is
therapy. First-line therapy of uncomplicated P. vivax mal-
aria is chloroquine. Nevertheless, several cases have been
reported describing the presence of chloroquine-resistant
P. vivax isolates in a number of areas throughout Asia
and Oceania, including the Indian subocontinent [15,16].
In addition, a mixed infection could not be ruled out. In-
deed, P. falciparum can account for mild cases of malaria
in pregnant women who left an endemic country, be-
cause the reduction of immunity related to pregnancy
might result in a recrudescence of low-level parasitaemia
even several months later [17,18]. Accordingly, the I.D.
specialist chose quinine sulphate as elective treatment.
Moreover, in order to prevent P. vivax relapsing infection
by eradicating the dormant forms, primaquine con-
stitutes the standard therapy. However, because prima-
quine can induce haemolytic anaemia in persons affected
by G6PD deficiency, it is contraindicated in pregnant
women given the unknown neonatal G6PD status [19].
Hence, the patient started primaquine treatment after
delivery.
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born must be assessed immediately at birth. Thin blood
smears were performed on the umbilical and peripheral
blood, detecting no parasites. Search for plasmodial
antigens was negative, too. Nonetheless, it is unclear
whether the oligohydramnios was a foetal adverse out-
come of malaria or a pregnancy complication unrelated
to the maternal infection. The histological examination
of the placenta is of great significance for the diagnosis
of P. falciparum, may be useful as a confirmation test in
non-falciparum malaria, and may be predictive of ad-
verse outcomes in the newborn [20,21]. Placental hist-
ology was investigated and revealed no sign of infection.
However, unlike P. falciparum, P. vivax rarely correlates
with pathological evidence of infection, due to its typical
lack of cytoadherence to placenta [10], and a negative
result of the histological exam does not rule out the
presence of P. vivax within the placenta. In addition, the
correlation between maternal infection and adverse out-
comes in the newborn needs further investigation, and
the effects of P. vivax malaria during pregnancy have
not been fully characterized. Therefore, the progressive
contraction of the amniotic fluid might be explained by
an ongoing P. vivax infection, which was not detected
by placental examination. Lastly, since the amniotic fluid
index started decreasing before the initiation of therapy,
the quinine treatment was unlikely to account for the
oligohydramnios. No other maternal or placental causes
of oligo-anhydramnios were found.
Conclusions
The pathogenesis of adverse outcomes in pregnancy-
related Plasmodium vivax malaria is still poorly known,
and the management of malaria in pregnant women can
be challenging. Every febrile or anaemic pregnant patient
with a previous stay in an endemic area should be
screened for malaria. The long latency of P. vivax mal-
aria dictates the inclusion of such infection in the differ-
ential diagnosis, in so far as the suspicion is supported
by epidemiological data. Placental examination should
be recommended upon delivery: evidence of malarial in-
fection might provide useful insights on the pathogenesis
of congenital malaria as well as the occurrence of poten-
tial complications in the newborn. However, a negative
result does not exclude an active non-falciparum malar-
ial infection. Future studies should investigate the link
between oligo-anhydramnios and pregnancy-associated
P. vivax malaria.
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